{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:11:37Z","timestamp":1760058697046,"version":"build-2065373602"},"reference-count":31,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Selecting appropriate disease-modifying drugs (DMDs) is crucial for optimizing treatment and slowing disease progression in multiple sclerosis (MS). Real-world studies assess drug efficacy and usage in routine clinical practice. Therefore, the goal of this study was to determine the efficacy and safety of oral drug therapy in patients with relapsing\u2013remitting multiple sclerosis and the particularities of adherence to the therapy. Materials and Methods: A retrospective and prospective study was conducted at the Neurology Clinic of the Kaunas Clinics of the Lithuanian University of Health Sciences. The medical records of patients with relapsing\u2013remitting multiple sclerosis (RRMS) were reviewed. The retrospective study included 286 patients, and the prospective study included 175 patients. Results: The study population included 131 patients on teriflunomide (TFN), 53 on dimethyl fumarate (DMF), 37 on fingolimod (FTY), and 65 on cladribine (CLAD). The overall absolute reduction in the ARR over 4 years of treatment was higher in the second-line (FTY and CLAD) group (\u22122.00) compared with the first-line (\u22120.99) group (TFN and DMF). The total EDSS scores of patients who received FTY and CLAD were higher in the second (3.09, p = 0.024), third (3.94, p = 0.015), and fourth (3.6, p = 0.002) years of treatment, compared with the patients of first-line therapy. MRI revealed that the number of contrast-enhancing and new lesions was lower among patients taking second-line drugs in the second year (4.7% and 18.6%, respectively). The worst adherence to the drug therapy due to forgetfulness was observed in the DMF group (30.8%). Lymphopenia was less frequent in the TFN group (93.1%) and more frequent in the FTY group (86.5%) (p &lt; 0.001). Conclusions: Over four years, second-line patients had greater ARR reduction, fewer MRI lesions, and higher EDSS from year two. DMF showed the lowest adherence, mainly due to patient forgetfulness, while lymphopenia occurred most frequently with FTY.<\/jats:p>","DOI":"10.3390\/medicina61040762","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T04:27:06Z","timestamp":1745209626000},"page":"762","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of the Efficacy, Safety, and Adherence to Oral Drug Therapy in Patients with Relapsing\u2013Remitting Multiple Sclerosis"],"prefix":"10.3390","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-4741-3296","authenticated-orcid":false,"given":"Paulius","family":"S\u0117d\u017eius","sequence":"first","affiliation":[{"name":"Department of Neurology, Lithuanian University of Health Sciences, A. Mickevi\u010diaus Str. 9, LT-44307 Kaunas, Lithuania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dalia","family":"Musneckien\u0117","sequence":"additional","affiliation":[{"name":"Department of Neurology, Lithuanian University of Health Sciences, A. Mickevi\u010diaus Str. 9, LT-44307 Kaunas, Lithuania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1212\/WNL.0000000000000768","article-title":"Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity","volume":"83","author":"Browne","year":"2014","journal-title":"Neurology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition","volume":"26","author":"Walton","year":"2020","journal-title":"Mult. Scler."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: The 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/ana.24747","article-title":"Long-term evolution of multiple sclerosis disability in the treatment era","volume":"80","author":"Cree","year":"2016","journal-title":"Ann. Neurol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","article-title":"Multiple sclerosis","volume":"372","author":"Compston","year":"2008","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"104068","DOI":"10.1016\/j.lpm.2021.104068","article-title":"Update on treatment in multiple sclerosis","volume":"50","author":"Callegari","year":"2021","journal-title":"Presse. Med."},{"key":"ref_7","first-page":"639","article-title":"Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in US commercial claims data","volume":"27","author":"Engmann","year":"2021","journal-title":"J. Manag. Care. Spec. Pharm."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"102521","DOI":"10.1016\/j.msard.2020.102521","article-title":"An analysis of first-line disease-modifying therapies in patients with relapsing-remitting multiple sclerosis using the French nationwide health claims database from 2014\u20132017","volume":"46","author":"Vermersch","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1177\/1352458517751049","article-title":"ECTRIMS\/EAN Guideline on the pharmacological treatment of people with multiple sclerosis","volume":"24","author":"Montalban","year":"2018","journal-title":"Mult. Scler."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"104157","DOI":"10.1016\/j.msard.2022.104157","article-title":"Post marketing new adverse effects of oral therapies in multiple sclerosis: A systematic review","volume":"68","author":"Sahraian","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Fischer, S., Proschmann, U., Akg\u00fcn, K., and Ziemssen, T. (2021). Lymphocyte Counts and Multiple Sclerosis Therapeutics: Between Mechanisms of Action and Treatment-Limiting Side Effects. Cells., 10.","DOI":"10.3390\/cells10113177"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s40120-021-00319-3","article-title":"Adherence to and persistence with disease-modifying therapies for multiple sclerosis over 24 months: A retrospective claims analysis","volume":"11","author":"Pardo","year":"2022","journal-title":"Neurol. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e01921","DOI":"10.1002\/brb3.1921","article-title":"The Danish Multiple Sclerosis Registry","volume":"11","author":"Magyari","year":"2021","journal-title":"Brain Behav."},{"key":"ref_14","unstructured":"(2024, September 25). Emsp. Available online: https:\/\/emsp.org\/our-members\/lithuania-lithuanian-multiple-sclerosis-union\/."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1177\/13524585221137502","article-title":"Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry","volume":"29","author":"Spelman","year":"2023","journal-title":"Mult. Scler."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"104791","DOI":"10.1016\/j.msard.2023.104791","article-title":"Comparative effectiveness of cladribine tablets versus fingolimod in the treatment of highly active multiple sclerosis: A real-world study","volume":"76","author":"Brownlee","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1007\/s13311-023-01416-x","article-title":"Dimethyl Fumarate or Teriflunomide for Relapsing-Remitting Multiple Sclerosis: A Meta-analysis of Post-marketing Studies","volume":"20","author":"Prosperini","year":"2023","journal-title":"Neurotherapeutics"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e1811","DOI":"10.1212\/WNL.0000000000007314","article-title":"Comparative effectiveness of teriflunomide and dimethyl fumarate: A nationwide cohort study","volume":"92","author":"Buron","year":"2019","journal-title":"Neurology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1111\/ene.16044","article-title":"Comparative analysis of dimethyl fumarate and teriflunomide in relapsing-remitting multiple sclerosis","volume":"30","author":"Lorscheider","year":"2023","journal-title":"Eur. J. Neurol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e635","DOI":"10.1212\/WNL.0000000000007938","article-title":"Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis","volume":"93","author":"Laplaud","year":"2019","journal-title":"Neurology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1093\/brain\/awac016","article-title":"How patients with multiple sclerosis acquire disability","volume":"145","author":"Lublin","year":"2022","journal-title":"Brain"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1136\/jnnp-2018-319831","article-title":"Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis","volume":"90","author":"Kalincik","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S1474-4422(11)70023-0","article-title":"Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: A post-hoc and subgroup analysis","volume":"10","author":"Giovannoni","year":"2011","journal-title":"Lancet Neurol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1007\/s00415-012-6775-0","article-title":"MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study","volume":"260","author":"Comi","year":"2013","journal-title":"J. Neurol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2147\/CEOR.S130334","article-title":"Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis","volume":"9","author":"Burks","year":"2017","journal-title":"Clinicoecon. Outcomes Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/ane.13301","article-title":"Medication adherence\/persistence among patients with active multiple sclerosis in Finland","volume":"142","author":"Kuusisto","year":"2020","journal-title":"Acta Neurol. Scand."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Ko\u0142tuniuk, A., and Chojdak-\u0141ukasiewicz, J. (2022). Adherence to Therapy in Patients with Multiple Sclerosis-Review. Int. J. Environ. Res. Public Health., 19.","DOI":"10.3390\/ijerph19042203"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/WNF.0b013e3181cbf825","article-title":"Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis","volume":"33","author":"Chun","year":"2010","journal-title":"Clin. Neuropharmacol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.msard.2015.11.006","article-title":"Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions","volume":"5","author":"Comi","year":"2016","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_31","first-page":"73","article-title":"Safety and persistence of dimethyl fumarate as a treatment for relapsing-remitting multiple-sclerosis","volume":"45","year":"2020","journal-title":"Farm. Hosp."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/4\/762\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:18:35Z","timestamp":1760030315000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/4\/762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,21]]},"references-count":31,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["medicina61040762"],"URL":"https:\/\/doi.org\/10.3390\/medicina61040762","relation":{},"ISSN":["1648-9144"],"issn-type":[{"type":"electronic","value":"1648-9144"}],"subject":[],"published":{"date-parts":[[2025,4,21]]}}}